Author

J. Pierga

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort.

Clinical variables alone had limited predictive value, supporting the need for molecular and immune biomarkers to better identify this subgroup of patients with HER2-positive metastatic breast cancer.

T. Grinda, M. Carton, S. Morganti et al. · Breast · 0 citations

Sep 2026

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

BACKGROUND Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer and a low-risk 70-gene signature (MammaPrint®). However, the contribution of the 70-gene signature in high-risk subgroups by nodal involvemen...

Robbert C. A. M. Gielen, C. Poncet, L. J. van 't Veer et al. · European Journal of Cancer · 0 citations